VERV: Ridgeway Acquisition Corporation, a wholly owned subsidiary of Eli Lilly (LLY), commenced the tender offer to acquire Verve Therapeutics (VERV) for $10.50 per share in cash. The offer will expire on July 23, 2025.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok